Search

Two new bifunctional chelators that are derivatives of the bis(thiosemicarbazone) ATSMH(2) proligand have been prepared, one with two phenyl carboxylate substituents on the exocyclic nitrogens (L(1)H(2)) and one with a single phenyl carboxylate (L(2)H(2)). The new ligands have been characterised by NMR spectroscopy, mass spectrometry and in the case of L(1)H(2) by X-ray crystallography. The copper, nickel and zinc complexes of the new ligands have been synthesised and characterised. Electrochemical measurements show that the copper(II) complexes undergo a reversible reduction attributable to a Cu(II)/Cu(I) process. The new proligands have been tethered to the N-alpha-Boc-protected amino acids lysine and ornithine using solution and solid phase methods. The new amino acid conjugates form copper complexes and the complexes have been characterised by mass spectrometry and electronic spectroscopy. The bifunctional chelator L(2)H(2) has been conjugated to the tumour targeting peptide octreotide and the new ATSMH(2)-octreotide conjugate and its copper complex have been characterized by mass spectrometry. These new systems have the potential to be used for new targeted copper radiopharmaceuticals for imaging and therapy.

Imidazolium groups have been successfully incorporated into the structure of a "picket fence" porphyrin molecule to produce a novel tetra-imidazolium zinc metalloporphyrin anion receptor. UV/visible spectroscopic studies reveal that this receptor is selective for sulfate anions, capable of strongly complexing sulfate in competitive water-DMSO (5 : 95) solvent mixtures. Cyclic and square wave voltammetric studies demonstrate the receptor's ability to sense a variety of anions electrochemically.

Ethylene polymerisation productivities of tris(pyrazolyl)methane-supported catalysts [Ti(NR){HC(Me2pz)3}Cl2] show a dramatically different dependence on the imido R-group compared to those of their TACN analogues, attributed to differences in fac-N3 donor topology; when treated with AliBu3, the zwitterionic tris(pyrazolyl)methide compound [Ti(N-2-C6H4tBu){C(Me2pz)3}Cl(THF)] also acts as a highly active, single site catalyst (TACN = 1,4,7-trimethyltriazacyclononane).

Two new thiosemicarbazone-pyridylhydrazine (THYNIC) hybrid ligands have been synthesized. Copper(II) and copper(I) complexes of the ligands have been prepared and characterized by X-ray crystallography. Cyclic voltammetry measurements show that the copper(II) complexes undergo quasi-reversible reductions at biologically accessible potentials. One of the ligands, bearing a pendant carboxylate arm, has been conjugated to N-alpha-(tert-butoxycarbonyl)-L-lysine.

Reaction of the dimeric zirconium imido compound [Zr2(mu-NAr)2Cl4(THF)4] with tris(3,5-dimethylpyrazolyl)methyl silane very selectively gave [Zr{(Me2pz)2Si(Me)NAr}Cl3] (1), a highly active pre-catalyst for ethylene polymerisation; a more general and versatile route to N3 donor heteroscorpionate compounds was achieved via the protio ligand (Me2pz)2CHSi(Me)2N(H)iPr for which neutral and cationic organometallic Group 3 and 4 derivatives are reported (Ar = 2,6-C6H(3)iPr2).

The uptake of zinc bis(thiosemicarbazone) complexes in human cancer cells has been studied by fluorescence microscopy and the cellular distribution established, including the degree of uptake in the nucleus.

A new method for the synthesis of low to intermediate oxidation state rhenium complexes containing a bifunctional ligand has been developed. Reaction of [ReO(4)](-) with substituted phenylhydrazines and triphenylphosphine in acetonitrile in the presence of HCl allows the isolation of [ReCl(2)(NNC(6)H(4)-4-R)(NCCH(3))(PPh(3))(2)] (where R = OCH(3), Cl, or CO(2)CH(3)). The substituted hydrazine acts as both a reductant and source of a monodentate diazenide ligand. The compounds have all been characterized in the solid state by X-ray crystallography and in the solution state by NMR, electrospray mass spectrometry, and HPLC. Cyclic voltammetry measurements show that the mono-diazenide complexes undergo a reversible oxidation.